PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£166,670
Buildy is an online platform that aims at making construction hiring easy by eliminating the expensive middlemen, thereby, saving time and money for both employers and employees. The platform was shortlisted as the Best Recruitment Innovation at Building Innovation Awards. Buildy has already signed up around 100 tradespeople and 46 employers. The company will streamline the hiring process through automation of job by bidding for jobs, matching algorithms, ratings, online chat, reviews, and providing the skilled workers and tradespeople more control via a better user interface. With the proceeds, the company will seek to fast track the Buildy app and help the company become the top recognised brand in construction staff hiring.
days to go:
Expired
investment:
£17,380
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go:
Expired
investment:
£1,149,999
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
Nutrifix is an app that locates healthy meals nearby or selects recipes or delivery options all tailored to you bodies needs. The app is like having a personal nutritionist in your pocket and is in a growing sector as the global value of mobile health solutions is set to reach 83,000,000,000 by 2022.
days to go:
Expired
investment:
£194,310
Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
days to go:
Expired
investment:
£193,219
